Whether to resubmit, meet, or pause the program from CMC comparability

Situation

An AdCom briefing document that overstates subgroup findings put CMC comparability package for a site change in front of pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / Clinical and Evidence Strategy close is to resubmit, meet, or from CMC comparability package for a site change, and the live options are To resubmit, meet,, Pause the program.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• The population in CMC comparability package for a site change is the one an AdCom briefing document that overstates subgroup findings named, so To resubmit, meet, follows for this Clinical and Evidence Strategy file.
• The population in CMC comparability package for a site change is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the program is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained an AdCom briefing document that overstates subgroup findings before CMC comparability package for a site change arrived; no new Clinical and Evidence Strategy path.
• Provenance on CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings is broken; do not pick To resubmit, meet, or Pause the program yet.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

Recommendation